filmov
tv
Clarifying the mechanism of EGFR inhibition in KRAS G13D colorectal cancer
Показать описание
McFall, et al. "Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors." Cell Communication and Signaling (2020)
Clarifying the mechanism of EGFR inhibition in KRAS G13D colorectal cancer
Afatinib inhibits EGFR Receptor activation
EGFR/Ras Pathway Relay Race
The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors. 02
Significance of TGF-Alpha and EGFR in head and neck cancer, and how Erlotinib treats it.
discovery of BLU-945, an EGFR mutant inhibitor - drug annotations
Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum
Overcoming Resistance to EGFR Inhibitors in NSCLC
IL-36γ induction underlies EGFR inhibitor-associated skin toxicity
Response to systemic anti-cancer therapy in uncommon EGFR mutations
Sotorasib,FDA,Lumakras amgen 510,non-small cell lung cancer
Distinguished Lecture Series | How Cancer Protein EGFR Transmits Signals into the Cell | TSB
Molecular Testing for EGFR Mutations: What Pathologists Need to Know
Cetuximab mode of action
Dermatologic Side Effects of EGFR-TKIs - 2022 Program: Targeted Therapies Forum
Acquired resistance to anti-EGFR therapy in colorectal cancer
Current and Future Implications of EGFR TKI in Neoadjuvant Setting in Locally Advanced NSCLC
What Are the Implications of KRAS Mutations in Colon Cancer?
Deciphering the data in EGFR - Mutant NSCLC
Mitigating resistance in KRAS-driven cancers
Таргетная терапия рака легких с мутацией EGFR, ROS1, BRAF V600E, HER2 и др. - Др Елизаветa Дудник...
Gaining multi-dimensional insights into cancer heterogeneity: Co-analysis of CTCs and ctDNA...
The KRAS Gene and Colon Cancer in Men
KRAS Inhibitor Gets CHMP Nod for Lung Cancer
Комментарии